Helix Biopharma Corp.
HBP.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.83% | -5.97% | -138.73% | -35.81% | 24.01% |
| Total Depreciation and Amortization | -36.36% | 0.00% | -26.67% | 31.82% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 149.19% | -1,022.22% | 791.35% | -34.71% | -59.12% |
| Change in Net Operating Assets | 144.48% | 207.60% | 346.48% | 470.06% | -1,849.80% |
| Cash from Operations | 40.22% | 53.76% | 52.64% | 25.33% | -36.47% |
| Capital Expenditure | -- | -- | -87.50% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 167.05% | -150.00% | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 269,800.00% | -- | 2.53% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 271,214.29% | -- | 6.99% | -- | 100.20% |
| Foreign Exchange rate Adjustments | -- | -- | 63.39% | -172.84% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 210.43% | -201.84% | 169.23% | 139.44% | 3.53% |